• Citer

Final 10-year results of the Breast International Group 2-98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer

par Sonnenblick, Amir;Anderson, Michael;Lluch, Ana;Gnant, Michael;Goldhirsch, Aron;Di Leo, Angelo ;Barnadas, Agusti;Cortes-Funes, Hernan;Piccart-Gebhart, Martine ;Crown, John;Francis, Prudence;Abdel Azim, Hatem Hamdy ;de Azambuja, Evandro ;Nordenskjöld, B;Gutiérez, Jorge;Quinaux, Emmanuel;Mastropasqua, Mauro Giuseppe;Ameye, Lieveke
Référence European journal of cancer, 51, 12, page (1481-1489), 9436
Publication Publié, 2014-11

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Titre:	Final 10-year results of the Breast International Group 2-98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer
Auteur:	Sonnenblick, Amir; Anderson, Michael; Lluch, Ana; Gnant, Michael; Goldhirsch, Aron; Di Leo, Angelo; Barnadas, Agusti; Cortes-Funes, Hernan; Piccart-Gebhart, Martine; Crown, John; Francis, Prudence; Abdel Azim, Hatem Hamdy; de Azambuja, Evandro; Nordenskjöld, B; Gutiérez, Jorge; Quinaux, Emmanuel; Mastropasqua, Mauro Giuseppe; Ameye, Lieveke
Informations sur la publication:	European journal of cancer, 51, 12, page (1481-1489), 9436
Statut de publication:	Publié, 2014-11
Sujet CREF:	Cancérologie
Mots-clés:	Adjuvant taxanes
	Breast cancer
	ER positive
	Ki67
	Pooled analysis
Note générale:	SCOPUS: ar.j
Langue:	Anglais
Identificateurs:	urn:issn:0959-8049
	info:doi/10.1016/j.ejca.2015.03.018
	info:pii/S0959804915002853
	info:scp/84936846685